Necela Brian M, Su Weidong, Thompson E Aubrey
Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL 32224, USA.
Immunology. 2008 Nov;125(3):344-58. doi: 10.1111/j.1365-2567.2008.02849.x. Epub 2008 Apr 18.
The peroxisome proliferator-activated receptor gamma (PPARgamma) is expressed in macrophages and plays an important role in suppressing the inflammatory response. Lipopolysaccharides (LPS), which activate Toll-like receptor 4 (TLR4), reduced PPARgamma expression and function in peritoneal macrophages and macrophage cell lines. Moreover, pretreatment with the synthetic PPARgamma ligand, rosiglitazone did not prevent LPS-mediated downregulation of PPARgamma. Inhibition of PPARgamma expression was not blocked by cycloheximide, indicating that de novo protein synthesis is not required for LPS-mediated suppression of PPARgamma. Destabilization of PPARgamma messenger RNA (mRNA) was not observed in LPS-stimulated macrophages, suggesting that LPS regulates the synthesis of PPARgamma mRNA. LPS had no effect on PPARgamma expression in macrophages from TLR4 knockout mice, whereas LPS inhibited PPARgamma expression in cells that had been reconstituted to express functional TLR4. Targeting the TLR4 pathway with inhibitors of MEK1/2, p38, JNK and AP-1 had no effect on PPARgamma downregulation by LPS. However, inhibitors that target NEMO, IkappaB and NF-kappaB abolished LPS-mediated downregulation of PPARgamma in LPS-stimulated macrophages. Our data indicate that activation of TLR4 inhibits PPARgamma mRNA synthesis by an NF-kappaB-dependent mechanism. Low-density genomic profiling of macrophage-specific PPARgamma knockout cells indicated that PPARgamma suppresses inflammation under basal conditions, and that loss of PPARgamma expression is sufficient to induce a proinflammatory state. Our data reveal a regulatory feedback loop in which PPARgamma represses NF-kappaB-mediated inflammatory signalling in unstimulated macrophages; however, upon activation of TLR4, NF-kappaB drives down PPARgamma expression and thereby obviates any potential anti-inflammatory effects of PPARgamma in LPS-stimulated macrophages.
过氧化物酶体增殖物激活受体γ(PPARγ)在巨噬细胞中表达,并在抑制炎症反应中发挥重要作用。激活Toll样受体4(TLR4)的脂多糖(LPS)可降低腹膜巨噬细胞和巨噬细胞系中PPARγ的表达和功能。此外,用合成的PPARγ配体罗格列酮预处理并不能防止LPS介导的PPARγ下调。PPARγ表达的抑制未被环己酰亚胺阻断,这表明LPS介导的PPARγ抑制不需要从头合成蛋白质。在LPS刺激的巨噬细胞中未观察到PPARγ信使核糖核酸(mRNA)的稳定性下降,提示LPS调节PPARγ mRNA的合成。LPS对来自TLR4基因敲除小鼠的巨噬细胞中PPARγ的表达没有影响,而LPS抑制已重组表达功能性TLR4的细胞中PPARγ的表达。用MEK1/2、p38、JNK和AP-1的抑制剂靶向TLR4途径对LPS介导的PPARγ下调没有影响。然而,靶向NEMO、IkappaB和NF-kappaB的抑制剂消除了LPS刺激的巨噬细胞中LPS介导的PPARγ下调。我们的数据表明,TLR4的激活通过NF-kappaB依赖的机制抑制PPARγ mRNA的合成。巨噬细胞特异性PPARγ基因敲除细胞的低密度基因组分析表明,PPARγ在基础条件下抑制炎症,PPARγ表达的缺失足以诱导促炎状态。我们的数据揭示了一个调节反馈环,其中PPARγ在未受刺激的巨噬细胞中抑制NF-kappaB介导的炎症信号;然而,在TLR4激活后,NF-kappaB降低PPARγ的表达,从而消除PPARγ在LPS刺激的巨噬细胞中任何潜在的抗炎作用。